AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Why Did CEL-SCI Soar 66.7%? Saudi Partnership, Stock Split
Generated by AI AgentBefore the Bell
Friday, Jul 11, 2025 9:30 am ET1min read
On July 11, 2025, CEL-SCI's stock surged by 66.7% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.
CEL-SCI Corporation has announced a strategic partnership with a leading Saudi Arabian pharmaceutical company. This collaboration aims to advance the use of Multikine in the treatment of head and neck cancer, a move that could significantly impact the company's market position and future growth prospects.
In addition to this partnership,
has also performed a 1 for 30 reverse stock split. This action reduces the number of outstanding shares, which can lead to an increase in the stock price per share, potentially making the stock more attractive to certain investors.These developments highlight CEL-SCI's commitment to innovation and expansion in the biotechnology sector, particularly in the field of cancer treatment. The company's focus on boosting the immune system of cancer patients before surgery aligns with its mission to provide effective and groundbreaking therapies.
Before the Bell
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Rezolve AI (NASDAQ: RZLV) Rides AI Wave to 12.26% Surge on Strategic Alliances
Dec.05 2025
Build-A-Bear (BBW) Plunges 15.54% as Tariff Woes and Analyst Downgrade Spur Sell-Off
Dec.05 2025
Maravai Biosciences (MRVI) Shares Surge 5.41% as Life Sciences Momentum and Fiscal 2026 Outlook Drive Optimism
Dec.05 2025
SES AI Shares Soar 14.5% on AI Sector Optimism, Strategic Positioning
Dec.05 2025
ORCL Shares Surge 3.18% on AI-Driven Optimism Ahead of Earnings Report
Dec.05 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet